Insmed Inc (INSM)vsCartesian Therapeutics Inc. (RNAC)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RNAC
Cartesian Therapeutics Inc.
$6.07
-8.03%
HEALTHCARE · Cap: $174.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 21581% more annual revenue ($606.42M vs $2.80M). RNAC leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RNAC
Avoid18
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
16.8% revenue growth
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -70.3% — below average capital efficiency
Earnings declined 7.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RNAC
The strongest argument for RNAC centers on Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RNAC
The primary concerns for RNAC are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RNAC is a growth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
RNAC is growing revenue faster at 16.8% — sustainability is the question.
RNAC generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Cartesian Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?